Acetylcysteine

Acetylcysteine

SCHEMBL663702

CC(=O)N[C@@H](CS)C(=O)O.O=NS

nearest known ligand 0.84

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.84
KDM4E B2RXH2 1/20 0.84
THRB P10828 1/20 0.84
ALOX15 P16050 1/20 0.84
NFKB1 P19838 1/20 0.84
PTGS2 P35354 1/20 0.84
THPO P40225 1/20 0.84
RECQL P46063 1/20 0.84
BLM P54132 1/20 0.84
SMN1; SMN2 Q16637 1/20 0.84
ACE P12821 1/20 0.53
ALDH1A1 P00352 2/20 0.52
FOLH1 Q04609 3/20 0.46
CA1 P00915 2/20 0.37
CA2 P00918 2/20 0.37
GNPAT O15228 1/20 0.37
TGFBR1 P36897 2/20 0.36
FNTA P49354 1/20 0.35
FNTB P49356 1/20 0.35
LMNA P02545 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Acetylcysteine SCHEMBL3923959 0.92 MAPT (1.00) MAPTKDM4ETHRBALOX15NFKB1
Acetylcysteine SCHEMBL1384791 0.92 MAPT (1.00) MAPTKDM4ETHRBALOX15NFKB1
Acetylcysteine SCHEMBL3923962 0.92 MAPT (1.00) MAPTKDM4ETHRBALOX15NFKB1
Acetylcysteine SCHEMBL5292 0.92 MAPT (1.00) MAPTKDM4ETHRBALOX15NFKB1
Acetylcysteine SCHEMBL4437351 0.92 MAPT (1.00) MAPTKDM4ETHRBALOX15NFKB1
Acetylcysteine SCHEMBL5291 0.92 MAPT (1.00) MAPTKDM4ETHRBALOX15NFKB1
Acetylcysteine SCHEMBL3688241 0.92 MAPT (1.00) MAPTKDM4ETHRBALOX15NFKB1
Acetylcysteine SCHEMBL4437350 0.92 MAPT (1.00) MAPTKDM4ETHRBALOX15NFKB1
Acetylcysteine SCHEMBL149212 0.92 MAPT (1.00) MAPTKDM4ETHRBALOX15NFKB1
Acetylcysteine SCHEMBL4433756 0.92 MAPT (1.00) MAPTKDM4ETHRBALOX15NFKB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160231323-A1 PROTECTION OF TCR SIGNALING CHAINS IN CANCER PATIENTS AND ENHANCEMENT OF CAR-T CELL THERAPY Batu Biologics, Inc. (US) 2016-08-11 US claimed
US-20140030323-A1 CONTROLLED RELEASE OF N-ACETYLCYSTEINE (NAC) FOR REDUCTION OF SYSTEMIC AND/OR VASCULAR INFLAMMATION TIARA PHARMACEUTICALS, INC. (US) 2014-01-30 US claimed
US-20120046232-A1 COMPOSITIONS AND METHODS FOR REDUCING RELAPSE OF ADDICTIVE BEHAVIOR MEDICAL UNIVERSITY OF SOUTH CAROLINA 2012-02-23 US claimed
US-20110244045-A1 CONTROLLED RELEASE OF N-ACETYLCYSTEINE (NAC) FOR REDUCTION OF SYSTEMIC AND/OR VASCULAR INFLAMMATION TIARA PHARMACEUTICALS ,INC. (US) 2011-10-06 US claimed
WO-2009137827-A2 CONTROLLED RELEASE OF N-ACETYLCYSTEINE (NAC) FOR REDUCTION OF SYSTEMIC AND/OR VASCULAR INFLAMMATION TIARA PHARMACEUTICALS, INC. (US) 2009-11-12 WO claimed
US-20140030323-A1 CONTROLLED RELEASE OF N-ACETYLCYSTEINE (NAC) FOR REDUCTION OF SYSTEMIC AND/OR VASCULAR INFLAMMATION TIARA PHARMACEUTICALS, INC. (US) 2014-01-30 US disclosed
US-8524772-B2 Controlled release of N-acetylcysteine (NAC) for reduction of systemic and/or vascular inflammation TIARA PHARMACEUTICALS, INC. (US) 2013-09-03 US disclosed
US-20120046232-A1 COMPOSITIONS AND METHODS FOR REDUCING RELAPSE OF ADDICTIVE BEHAVIOR MEDICAL UNIVERSITY OF SOUTH CAROLINA 2012-02-23 US disclosed
US-20110244045-A1 CONTROLLED RELEASE OF N-ACETYLCYSTEINE (NAC) FOR REDUCTION OF SYSTEMIC AND/OR VASCULAR INFLAMMATION TIARA PHARMACEUTICALS ,INC. (US) 2011-10-06 US disclosed
US-20100105685-A1 S-Nitrosothiol Compounds and Related Derivatives GALLEON PHARMACEUTICALS, INC. 2010-04-29 US disclosed
US-20100035998-A1 COMBINATION S-NITROSOTHIOL PHARMACEUTICAL PRODUCTS FOR RESTORING NORMAL BREATHING RHYTHMS Galleon Pharmaceutical, Inc (US) 2010-02-11 US disclosed
WO-2009137827-A2 CONTROLLED RELEASE OF N-ACETYLCYSTEINE (NAC) FOR REDUCTION OF SYSTEMIC AND/OR VASCULAR INFLAMMATION TIARA PHARMACEUTICALS, INC. (US) 2009-11-12 WO disclosed
EP-2068903-A2 S-NITROSOTHIOL COMPOUNDS AND RELATED DERIVATIVES Galleon Pharmaceuticals, Inc. (US) 2009-06-17 EP disclosed
EP-1940369-A2 COMBINATION S-NITROSOTHIOL-BASED PHARMACEUTICAL PRODUCTS FOR RESTORING NORMAL BREATHING RHYTHM Galleon Pharmaceuticals (US) 2008-07-09 EP disclosed
WO-2008066603-A2 S-NITROSOTHIOL COMPOUNDS AND RELATED DERIVATIVES GALLEON PHARMACEUTICALS, INC. (US) 2008-06-05 WO disclosed
WO-2007035879-A2 COMBINATION S-NITROSOTHIOL-BASED PHARMACEUTICAL PRODUCTS FOR RESTORING NORMAL BREATHING RHYTHM GALLEON PHARMACEUTICALS (US) 2007-03-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140030323-A1 CONTROLLED RELEASE OF N-ACETYLCYSTEINE (NAC) FOR REDUCTION OF SYSTEMIC AND/OR VASCULAR INFLAMMATION IL6, IL1B, NACA MAPT 2103/4885KDM4E 4849/4885THRB 3934/4885
US-20120046232-A1 COMPOSITIONS AND METHODS FOR REDUCING RELAPSE OF ADDICTIVE BEHAVIOR GRM6, GRM5, GRM7 MAPT 3237/4885KDM4E 1271/4885THRB 1739/4885
US-20100105685-A1 S-Nitrosothiol Compounds and Related Derivatives NNMT, BHMT2, SQOR MAPT 2644/4885KDM4E 1106/4885THRB 1782/4885
US-20110244045-A1 CONTROLLED RELEASE OF N-ACETYLCYSTEINE (NAC) FOR REDUCTION OF SYSTEMIC AND/OR VASCULAR INFLAMMATION IL6, IL1B, NACA MAPT 2103/4885KDM4E 4849/4885THRB 3934/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.